Parag Meswani V - 28 Jan 2022 Form 3 Insider Report for Sio Gene Therapies Inc.

Role: Chief Commercial Officer
Signature: /s/ David Nassif, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 28 Jan 2022
Net transactions value: $0
Form type: 3
Filing time: 07 Feb 2022, 18:17:01 UTC
Next filing: 10 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SIOX	Common Stock						33,733	28 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SIOX	Stock Option (Right to Buy)							28 Jan 2022	Common Stock	15,625	$9.20	Direct	F1
holding	SIOX	Stock Option (Right to Buy)							28 Jan 2022	Common Stock	15,625	$9.20	Direct	F2
holding	SIOX	Stock Option (Right to Buy)							28 Jan 2022	Common Stock	20,875	$8.48	Direct	F3
holding	SIOX	Stock Option (Right to Buy)							28 Jan 2022	Common Stock	12,500	$8.48	Direct	F4
holding	SIOX	Restricted Stock Units							28 Jan 2022	Common Stock	25,333		Direct	F5, F6
holding	SIOX	Stock Option (Right to Buy)							28 Jan 2022	Common Stock	18,075	$5.63	Direct	F7
holding	SIOX	Restricted Stock Units							28 Jan 2022	Common Stock	8,033		Direct	F6, F8
holding	SIOX	Stock Option (Right to Buy)							28 Jan 2022	Common Stock	219,000	$2.47	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vested or vests, as applicable, over a period of four years with 25% of the shares of common stock underlying the option vested on November 26, 2019, and the remainder vested or vesting, as applicable, in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer through each such date.
F2	One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $24.00; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $40.00; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $56.00, in each case subject to the Reporting Person providing continuous service to the Issuer through each such date.
F3	The option vested or vests, as applicable, over a period of four years with 25% of the shares of common stock underlying the option vested on April 15, 2020, and the remainder vested or vesting, as applicable, in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer through each such date.
F4	One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $16.96; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $33.92; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $50.88, in each case subject to the Reporting Person providing continuous service to the Issuer through each such date.
F5	One-half of the restricted stock unit shall vest on April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.
F6	Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F7	The option vested or vests, as applicable, over a period of four years with 25% of the shares of common stock underlying the option vested on October 5, 2021, and the remainder vested or vesting, as applicable, in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer through each such date.
F8	One-half of the restricted stock unit shall vest on October 5, 2022 and October 5, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.
F9	The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock.